Blood clots are associated with life-threatening conditions such as sepsis, sickle cell disease, heart attack, and stroke.

FDA Approval: The FDA granted full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...